JAK inhibitor for the treatment of steroid refractory and life-threatening immune-related adverse events secondary to immune checkpoint inhibitors.
Bibliographic record
Abstract
2643 Background: Immune checkpoint inhibitors (ICIs) boost anti-tumor immune responses but carry the risk of off-target effects, manifesting as immune-related adverse events (irAEs). Approximately 20% of irAEs are refractory to steroids, requiring subsequent immunosuppressive therapies, while a smaller subset presents with fulminant reactions requiring multiple agents simultaneously. Although biologics like TNF and IL-6 inhibitors are often used, their targeting of single inflammatory pathways may be insufficient to resolve irAEs in these critical scenarios. We conducted a prospective study to assess the safety and efficacy of oral JAK inhibitors, molecules capable of rapidly modulating multiple inflammatory cytokine signals, in managing steroid-refractory or life-threatening irAEs. Methods: The MIRAE Biobank is a prospective cohort study of cancer patients treated with ICI at the Jewish General Hospital in Montreal, Canada. Patients with steroid refractory subjects with grade > 3 irAE or persistent grade 2 toxicity despite optimal therapy, as well as life-threatening irAEs in the first-line setting treated with JAK inhibitors were extracted from the database and their clinical data was summarized. Among those who survived at least 30 days post-JAK inhibitor, we compared characteristics of responders and non-responders. Responders were defined as resolution of the irAE to grade < 1 and < 10mg prednisone equivalents without any relapses during a 30-day period. Results: In this series, 29 patients were treated with JAK inhibitors for refractory or life-threatening irAEs. Mean age was 69 years, 34.5% were women, 82.8% received anti-programmed cell death protein-1 (PD-1) antibodies alone, and 13.8% patients were treated with the combination of anti-cytotoxic T lymphocyte antigen-4 and anti-PD-1 antibodies. Cancer types were primarily melanoma (10, 34.5%) and lung cancer (6, 20.7%). Primary irAEs for which JAK inhibitors were initiated included myocarditis (n=11), colitis (n=4), arthritis (n=4), hepatitis (n=4), encephalitis (n=2), pneumonitis (n=2), myasthenia gravis (n=1) and sicca (n=1). JAK inhibitors were used as second- (refractory to steroids alone), third- or fourth- or more line in 9, 11 and 9 patients, respectively. Median duration of JAK inhibitor exposure was 30.5 days. Among the 24 patients who survived at least 30 days, 17 (71%) responded after a median of 11 days from initiation of the JAK inhibitor. Interestingly, this included 6/8 patients with myocarditis, 4/4 with arthritis and 2/3 with colitis. Of those who responded to JAK inhibitor, 11/18 were steroid refractory and 6/6 were life-threatening cases requiring simultaneous treatment with steroids. Conclusions: This preliminary data suggests that JAK inhibitors may be effective at treating various types of steroid-refractory and life-threatening irAEs.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.000 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.000 | 0.001 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.005 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".